30th June 2021 Share Price Prediction, page-180

Haha sorry I should clarify.

Not undervalued at all from a current revenue point of view.

More undervalued from the future growth prospects. And from this I am likely very biased based on my understanding of the industry and the tech.

The independent papers being published and the uptake by surgeons is extremely promising, and I think that the companies estimates of revenue doubling yoy is likely an understatement.

While it's merely doubling now, I foresee it growing a bit more exponentially as it is used more and more, more hospitals get on board and start reordering, and as it starts to become standard of care for more indications.

Again I'm a bit of an optimist, maybe to a fault. I agree from current revenues it is overvalued, but for how derisked it is (compared to other companies that haven't cleared their stage 3 trials or have fda approval in America, and yet are valued at a few billion dollars, for instance) as a growth stock I think it's a great buying opportunity at this stage.